These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 32789350

  • 1. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
    Jayawardhana AMDS, Stilgenbauer M, Datta P, Qiu Z, Mckenzie S, Wang H, Bowers D, Kurokawa M, Zheng YR.
    Chem Commun (Camb); 2020 Sep 15; 56(73):10706-10709. PubMed ID: 32789350
    [Abstract] [Full Text] [Related]

  • 2. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
    Jayawardhana AMDS, Bhandari S, Kaspi-Kaneti AW, Kshetri M, Qiu Z, Cheline M, Shen H, Dunietz BD, Zheng YR.
    Dalton Trans; 2023 Aug 08; 52(31):10942-10950. PubMed ID: 37490033
    [Abstract] [Full Text] [Related]

  • 3. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
    BMC Cancer; 2016 Feb 23; 16():140. PubMed ID: 26906901
    [Abstract] [Full Text] [Related]

  • 4. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 5. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 05; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 6. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N, Yu JQ, Beale P, Fisher K, Huq F.
    Anticancer Res; 2012 Jan 01; 32(1):135-40. PubMed ID: 22213298
    [Abstract] [Full Text] [Related]

  • 8. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
    Yuan Y, Zhang CJ, Liu B.
    Chem Commun (Camb); 2015 May 21; 51(41):8626-9. PubMed ID: 25898264
    [Abstract] [Full Text] [Related]

  • 9. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.
    J Control Release; 2008 Oct 21; 131(2):100-6. PubMed ID: 18691617
    [Abstract] [Full Text] [Related]

  • 10. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
    Zhang Y, Guo G, Ma B, Du R, Xiao H, Yang X, Li W, Gao Y, Li Y, Jing X.
    Anticancer Drugs; 2015 Aug 21; 26(7):698-705. PubMed ID: 25811961
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM.
    J Inorg Biochem; 2015 Aug 21; 149():45-8. PubMed ID: 26021697
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 16. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F, Sun T, Xu Z, Wang Z, Kong W, To MW, Wang F, Zhu G.
    Dalton Trans; 2016 Aug 16; 45(33):13052-60. PubMed ID: 27430044
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
    Wang Y, Luo Z, Zhou D, Wang X, Chen J, Gong S, Yu Z.
    Biomater Sci; 2021 Jun 04; 9(11):4110-4119. PubMed ID: 33949442
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.